Omega-3 supplementation increases omega-3 fatty acids in lipid compartments that can be taken up by the brain independent of APOE genotype status: A secondary analysis from a randomised controlled trial1

BACKGROUND: Omega-3 fatty acid (OM3) intake is associated with a lower risk of developing Alzheimer’s disease, but individuals carrying the ɛ4 allele apolipoprotein E (APOE4) might not benefit from this prevention strategy. Indeed, they have OM3 into plasma free (FFA) and lysophosphatidylcholine (LPC) compartments, two forms brain can take-in. OBJECTIVE: To evaluate docosahexaenoic (DHA) eicosapentaenoic (EPA) concentrations in FFA LPC pre- post-OM3 supplementation APOE4 carriers non-carriers. DESIGN: Plasma samples 25 non-carriers before six months after receiving 2.5 g/d DHA+EPA daily were analyzed. DHA EPA LPC, compared by genotype. A secondary analysis investigated interaction between body mass index (BMI) APOE genotype status. RESULTS: There was no x supplement nor effect on FFA. However, there where increased all lipid compartment < 1-fold to 4-fold. Individuals low BMI had higher increase than those high BMI. CONCLUSIONS: both taking an supplement. increases